Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Shareholder Meeting (May 2024)
20 slides from Avecho Biotechnology's shareholder meeting presentation, May 30, 2024
Slide 1: Chair's Address & CEO Presentation
ASX Announcement 30 May 2024 Chair’s Address & CEO Presentation Melbourne, Australia, 30 May 2024: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), attaches the Chair’s Address and the Chief Executive Officer’s presentation for the Annual General Meeting of 30 May 2024 to be held
Slide 2: Avecho's major projects include delivering TPM enhanced products
Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock. See more here - av
Slide 3: Chair's Address
Chair’s Address Dear Shareholders, I am delighted to share a Company update on behalf of Avecho Biotechnology Limited to coincide with our Annual General Meeting (“AGM”) today. This Financial Year (FY23-24) has been a testament to our focus and perseverance as we enter our pivotal Phase III clinical
Slide 4: Expanded Board: Kathy Connell
> Expanded Board: Kathy Connell In late April, we welcomed Kathy Connell to the Avecho Board – an internationally recognised healthcare and life sciences leader with extensive investment and licensing expertise, who is ideally qualified to support the company in our efforts to realise the commercial
Slide 5: Annual General Meeting
ANNUAL GENERAL MEETING 30TH MAY 2024 www.avecho.com.au | ASX:AVE
Slide 6: Safe Harbour Statement
SAFE HARBOUR STATEMENT AVECHO BIOTECHNOLOGY This presentation, and any representations made before, during or after the presentation, may include forward- looking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not limited to: (1) the safety or
Slide 7: Clear Strategic Focus
CLEAR STRATEGIC FOCUS 1. Complete pivotal Phase III clinical trial for CBD capsule containing TPM® technology 2. License this and other TPM cannabinoid products into global markets May 2022 3 AVECHO BIOTECHNOLOGY May 2024 3
Slide 8: The Year Behind Us
THE YEAR BEHIND US May 2022 4 AVECHO BIOTECHNOLOGY May 2024 4
Slide 9: Company Snapshot
COMPANY SNAPSHOT Board AVE Corporate Summary Management Team Dr Greg Collier Total shares 3.17 Bn Chairman Dr Paul Gavin Chief Executive Officer Total options1 2.37 Bn Dr Ross Murdoch Non-Executive Director Dr Roksan Libinaki Chief Operating Officer Cash (end Q1 2024) A$4.6 M Matt McNamara Non-Execu
Slide 10: Insomnia Has Become a Major Problem Worldwide
INSOMNIA HAS BECOME A MAJOR PROBLEM WORLDWIDE Insomnia is broadly defined as difficulty initiating or 2 maintaining sleep. Insomnia affects 10-30% of the population, with 10-15% of the population classified as chronic. Insomnia can be a symptom of a range of other disorders, particularly mental heal
Slide 11: Insomnia Is of Increasing Interest in Australia
INSOMNIA IS OF INCREASING INTEREST IN AUSTRALIA 2 In Australia1: • 40% of Australians getting less sleep than they need • 59.4% Experience symptoms 3-4 times per week Avecho on Channel 9 News • Only 20% report their sleep is uninterrupted • Costs Australian economy $19.1 B per annum • Australian ins
Slide 12: Changing Competitive Landscape
CHANGING COMPETITIVE LANDSCAPE Four Australian companies pursued Phase IIb/III clinicals in insomnia targeting TGA registration - three failed Finalised trial Avecho is the last company in active clinical development design and timing will be • Avecho’s insomnia Phase III is significantly larger and
Slide 13: Phase III Protocol Review by the TGA
PHASE III PROTOCOL REVIEW BY THE TGA The TGA is yet to see a submission for OTC registration of cannabidiol Avecho met with the TGA in February to discuss the Phase III protocol and future submission plans. The TGA had no requested changes to the Phase III protocol, with Avecho’s program described a
Slide 14: Phase III Study Design
PHASE III STUDY DESIGN Based upon study design from FDA approved insomnia medications Assessments include; Avecho’s Phase III insomnia trial has been • Daily sleep diary to record nightly sleep. designed to maximise the chance of success. • Sleep questionnaire every two weeks. Compared to recent stu
Slide 15: Phase III Under Way
PHASE III UNDER WAY Trial Targets Eligible Patients so far • 519 patients in total • ~219 patients complete dosing to interim analysis • Trial commenced recruitment in March. • National media coverage has seen over 1750 people 30 register interest in participating in the study • Of these, 151 fulfil
Slide 16: Timelines to Interim Analysis - Major Go/No Go
TIMELINES TO INTERIM ANALYSIS - MAJOR GO/NO GO 2024 2025 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Phase III (interim) Results Interim Patient recruitment Analysis Dosing patients Interim Analysis Revised patient GO/NO GO numbers Phase III Trial
Slide 17: The Opportunity
THE OPPORTUNITY • De-risked Phase 3 trial underway – robust design reviewed by TGA • Potential to be the first over-the-counter CBD sleep capsule – first mover advantage • Outstanding partnering potential – significant interest from major pharmaceutical companies • Avecho’s TPM technology significan
Slide 18: New Cannabinoid Products
NEW CANNABINOID PRODUCTS THC TPM edibles Avecho has completed the optimisation of TPM cannabinoid edibles • Edibles have rapid onset, increased strength and longer duration • Applications to the pharmaceutical, medicinal and recreational markets • In discussions with partners regarding commercialisa
Slide 19: The Year in Front of Us
THE YEAR IN FRONT OF US /s Recruitment updates May 2022 15 AVECHO BIOTECHNOLOGY May 2024 15
Slide 20: Questions Welcome
QUESTIONS WELCOME Dr Paul Gavin Chief Executive Officer T. +61 3 9002 5000 E. pgavin@avecho.com.au Melbourne Office Unit A8, 2A Westall Road Hallmarc Business Park Clayton VIC 3168 Australia T: +61 3 9002 5000 E: info@avecho.com.au
Avecho Biotechnology — Shareholder Meeting (May 2024) on 6ix